John S. Abrams, PhD, discusses some of the cutting-edge work he’s involved in and what he’s looking forward to at this year's Emerald Conference.
As the Emerald Conference quickly approaches, we spoke with John S. Abrams, PhD-Principal of Abrams Bioconsulting, Chairman and CSO of The CESC, and CSO of Orion GMP Solutions-to get some insider information on the type of science we can expect to hear at this year’s conference. Here, Abrams discusses some of the cutting-edge work he’s involved in and what he’s looking forward to at the conference.
How is the industry establishing regulations and compliance in a scientifically sound and evidence-based manner?
John S. Abrams: Establishing regulations and compliance in a scientifically sound and evidence-based manner is a slow and evolving process. It doesn't happen quickly, and sometimes it is not straightforward. As we emerge from the shadows of prohibition, we have to be mindful of not having to reinvent the wheel each time.
We should look to other industries where there are relevant, useful, and validated approaches. There are, however, some approaches which come from the early days of back-alley cannabis labs that need to be scrutinized and re-evaluated in the light of good scientific practices. This is particularly relevant in the context of designing sampling plans. Additionally, analysts in this field need to realize that their methods should be open, discussed, and reviewed. This is neither the time nor the place to be considering analytical approaches as proprietary-we must collaborate.
Finally, I would like to add that the industry should collectively support federal descheduling as quickly as possible to allow interstate transport of samples for analytical purposes. That way, the best and most advanced analytical facilities can help establish answers to the more difficult questions in cannabis science.
What is the significance of multivariate statistics and design of experiments (DOE) in cannabis strain chemotype profiling?
Abrams: Cannabis is a complex botanical. It contains a myriad of natural products. In some combinations they confer the desirable properties of the cannabis commodity. Statistical approaches like multivariate analysis can be useful for simplifying that complexity. The goal of multivariate analysis is to come up with a limited set of parameters, of answers to communicating the complexity of cannabis natural product content that product users can more easily understand, and to tie their experience to approaches such as design of experiments (DOE), provide a framework for cultivators trying to understand what key factors may affect cannabinoid and terpenoid production. These are the key elements defining cannabis chemotypes.
DOE allows for simplification and reduction in the number of different experimental runs required to draw meaningful conclusions. It is fundamentally a way to get more bang for your research buck.
How has applying antibody development and immunoassay-based technologies advanced cannabis product assays?
Abrams: Like so much in the cannabis science field, applying antibody development and immunoassay-based technologies to advance cannabis product assays is a developing story. We are actively pursuing the development of in-vitro cell-based bioassays to determine functional activity (what we really mean when we say "potency") of various cannabinoids such as THCA and CBDA. We rely on antibodies as tools to provide specificity and selectivity to such cannabinoid bioassays. This is one of the principal reasons I developed such anti-CBD(A) antibodies several years ago.
As a scientific committee member of the Emerald Conference, what do you look forward to most at the conference?
Abrams: As a scientific committee member of the Emerald Conference, what I’m looking forward to most at this year’s conference is the opportunity to foster collaboration and innovation with like-minded participants.
There are many different ways to become informed on cutting edge knowledge and state-of-the-art innovation including:
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.
Inside the University of Maryland School of Pharmacy’s Graduate Program in Medical Cannabis
September 16th 2024Leah Sera, PharmD, MA, the co-program director for the University of Maryland School of Pharmacy’s Graduate Studies in Medical Cannabis program sat down with Cannabis Science and Technology to discuss higher education in medical cannabis.
Studying the Evolution of Cannabis Education: Insights from Stockton University’s Course Instructors
September 13th 2024A leader in cannabis education in New Jersey, Stockton University offers a wide variety of courses to prepare its students to not only succeed in an ever-growing industry, but to also understand its complex history and shape its evolving future. Started six years ago, its Cannabis Studies Program continues its commitment to providing innovative and practical instruction to its students. Two influential figures in this space are Robert Mejia, Teaching Specialist in the Cannabis Studies Program, and Angela Speakman, Instructor in the Cannabis Studies Program. Here, they highlight the program’s practical approach to cannabis education, celebrate the success stories of graduates, discuss the National Cannabis Curriculum Convening, and address challenges in cannabis education and its role in the future.
Medical Cannabis Campaigning with Americans for Safe Access
September 4th 2024As discussions about the federal scheduling of cannabis continue, efforts by medical cannabis advocates are intensifying. One such advocate is Americans for Safe Access (ASA), a nonprofit organization founded by patients for patients. Since 2002, ASA has been championing the rights of medical cannabis patients and has recently launched new campaigns and strategies to refocus attention on patient needs. In this interview, Steph Sherer, founder and president of ASA, reflects on past successes in medical cannabis advocacy, shares her perspective on recent cannabis and hemp policymaking, and outlines the next steps for advancing a unified medical cannabis message on Capitol Hill—a message that could bring about the changes patients have long awaited.
Insights on Cannabis Testing Challenges and Industry Standards: An Interview with Douglas Duncan
August 9th 2024In light of recent headlines concerning cannabis laboratories throughout the country, Cannabis Science and Technology reached out to Douglas Duncan, Laboratory Director of Kairos Labs in Detroit, MI and member of our Editorial Advisory Board for more information. In this interview, Duncan shares his perspectives on lab shopping, major challenges in the industry today, and innovations in cannabis testing laboratories for the future. He also shares insights into consumer practices and the potential effects of a federal rescheduling of cannabis.